FHTX Foghorn Therapeutics Inc
P/E
--
Forward P/E
--
Price/Sales
3.233
Beta
3.01
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Foghorn Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Analysts expect Foghorn Therapeutics to report a Q3 2026 loss of $0.23 per share on revenue of $7.15 million, while the current stock price of $7.85 sits well...
Foghorn Therapeutics third quarter 2026 revenue reached $83.5M while cash runway extended into 2029
Foghorn Therapeutics reported a significant increase in collaboration revenue for the third quarter of 2026, primarily driven by non-recurring accounting...
Foghorn Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Foghorn Therapeutics is expected to report Q3 2026 revenue of approximately $6.39 million and a consensus EPS of -$0.23, while the stock's current price of...